Premium
Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
Author(s) -
Murphy G.P.,
Tjoa B.A.,
Simmons S.J.,
Ragde H.,
Rogers M.,
Elgamal A.,
Kenny G.M.,
Troychak M.J.,
Salgaller M.L.,
Boynton A.L.
Publication year - 1999
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19990401)39:1<54::aid-pros9>3.0.co;2-u
Subject(s) - medicine , prostate cancer , prostate , prostate specific antigen , prostatic acid phosphatase , urology , cancer , oncology , immune system , clinical trial , immunology
BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA‐A2‐specific prostate‐specific membrane antigen (PSMA) peptides (PSM‐P1 and ‐P2). This report describes the evaluation of 37 subjects admitted with presumed local recurrence of prostate cancer after primary treatment failure. METHODS All subjects received six infusions of DC pulsed with PSM‐P1 and ‐P2 at 6‐week intervals. Clinical monitoring was conducted pre‐, during, and post‐phase II study. Data included: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, ProstaScint® scan, and chest X‐ray, as well as other assays to monitor cellular and humoral immune responses. RESULTS One complete and 10 partial responders were identified from this group based on National Prostate Cancer Project criteria, or on a 50% reduction of prostate‐specific antigen (PSA), or on a significant resolution in lesions (biopsy‐proven when possible) on ProstaScint® scan. CONCLUSIONS About 30% of study participants in this group showed a positive response at the conclusion of the trial. This study suggests that DC‐based cancer vaccines may provide an alternative therapy for prostate cancer patients whose primary treatment failed. Prostate 39:54–59, 1999. © 1999 Wiley‐Liss, Inc.